RT Journal Article
SR Electronic
T1 Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors
JF Molecular Pharmacology
JO Mol Pharmacol
FD American Society for Pharmacology and Experimental Therapeutics
SP 338
OP 348
DO 10.1124/mol.107.041236
VO 73
IS 2
A1 Stuart L. Emanuel
A1 Terry V. Hughes
A1 Mary Adams
A1 Catherine A. Rugg
A1 Angel Fuentes-Pesquera
A1 Peter J. Connolly
A1 Niranjan Pandey
A1 Sandra Moreno-Mazza
A1 Jeannene Butler
A1 Virna Borowski
A1 Steven A. Middleton
A1 Robert H. Gruninger
A1 Jennifer R. Story
A1 Cheryl Napier
A1 Beth Hollister
A1 Lee M. Greenberger
YR 2008
UL http://molpharm.aspetjournals.org/content/73/2/338.abstract
AB JNJ-28871063 is a potent and highly selective pan-ErbB kinase inhibitor from a novel aminopyrimidine oxime structural class that blocks the proliferation of epidermal growth factor receptor (EGFR; ErbB1)- and ErbB2-overexpressing cells but does not affect the growth of non-ErbB-overexpressing cells. Treatment of human cancer cells with JNJ-28871063 inhibited phosphorylation of functionally important tyrosine residues in both EGFR and ErbB2 and blocked downstream signal transduction pathways responsible for proliferation and survival. A single dose of compound reduced phosphorylation of ErbB2 receptors in tumor-bearing mice, demonstrating target suppression in vivo. Tissue distribution studies show that JNJ-28871063 crosses the blood-brain barrier and penetrates into tumors, where it is able to accumulate to higher levels than those found in the plasma. JNJ-28871063 showed oral antitumor activity in human tumor xenograft models that overexpress EGFR and ErbB2. In an intracranial ErbB2-overexpressing tumor model, JNJ-28871063 extended survival relative to untreated animals. The brain is a primary site of metastasis for EGFR-overexpressing lung cancers and ErbB2-overexpressing breast cancers. Therefore, the ability to penetrate into the brain could be an advantage over existing therapies such as trastuzumab (Herceptin) and cetuximab (Erbitux), which are antibodies and do not cross the blood-brain barrier. These results show that JNJ-28871063 is orally bioavailable, has activity against EGFR and ErbB2-dependent tumor xenografts, and can penetrate into the brain and inhibit ErbB2-overexpressing tumor growth. The American Society for Pharmacology and Experimental Therapeutics